Obviously the staff reduction included people [pharmavigilance & such] working on the trial. Command was the major activity of the company. I don't expect to hear much from management until they finalize their plans. Hopefully to include a research partnership.
Don't know if the price reflects a loss of confidence or complete disappointment. Some companies, such as Infinity, have had many failures & still retain investor confidence. I don't know of any other $70 million biotech with over $100million & Verastems exposure. Prior to the offering my recommendation was that they add a research partner. This would have enabled a higher price - particularly if the partner participated in the offering. Instead they sold stock into the open market prior to the offering! Boston Biomedical & OncoMed are examples of csc that that made deals early. VSTM is still determined to go it alone. Near term it would be interesting to know the new owners of the stock & of course the results of the ovarian trial.